1
|
Yadav S, Shaikh Z, Mahajan A, Lokhandwala Y. Coronary sinus diverticulum and partial left-sided inferior vena cava in a patient with atrial fibrillation and Wolff-Parkinson-White syndrome. J Postgrad Med 2021; 67:247-248. [PMID: 33818521 PMCID: PMC8706542 DOI: 10.4103/jpgm.jpgm_970_20] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
Affiliation(s)
- S Yadav
- Department of Cardiology, Lokmanya Tilak Municipal General Hospital, Mumbai, Maharashtra, India
| | - Z Shaikh
- Department of Cardiology, Lokmanya Tilak Municipal General Hospital, Mumbai, Maharashtra, India
| | - A Mahajan
- Department of Cardiology, Lokmanya Tilak Municipal General Hospital, Mumbai, Maharashtra, India
| | - Y Lokhandwala
- Department of Cardiology, Holy Family Hospital, Mumbai, Maharashtra, India
| |
Collapse
|
2
|
Franchi F, Rollini F, Kairouz V, Rivas J, Rivas A, Agarwal M, Briceno M, Wali M, Nawaz A, Silva G, Shaikh Z, Soffer D, Zenni MM, Bass TA, Angiolillo DJ. P1930Pharmacodynamic effects of vorapaxar as an add-on antiplatelet therapy in patients with and without diabetes mellitus: the optimizing anti-platelet therapy in diabetes mellitus (OPTIMUS)-5 study. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz748.0677] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Vorapaxar (Vora) is a protease-activated receptor (PAR)-1 inhibitor which when added to dual antiplatelet therapy (DAPT) in patients with a history of myocardial infarction (MI) or with peripheral arterial (PAD) reduces thrombotic cardiovascular events at the expense of increased bleeding. The efficacy of Vora is enhanced in patients with diabetes mellitus (DM) compared to non-DM. However, the differential pharmacodynamic (PD) effects of Vora in DM vs non-DM patients are unknown. Moreover, although withdrawal of aspirin has emerged as a strategy to reduce bleeding when adjunctive antithrombotic therapies are used, the PD effects of Vora after stopping aspirin in DAPT treated patients is unknown.
Purpose
To assess the PD effects of Vora in addition to standard DAPT as well as in combination with clopidogrel following aspirin withdrawal in patients with and without DM.
Methods
This was a prospective parallel-design PD study conducted in post-MI or PAD patients with and without DM. Patients on DAPT with aspirin (81mg/qd) and clopidogrel (75mg/qd) were divided in two groups according to DM status. Each cohort was treated with Vora (2.5mg/qd) in addition to DAPT (i.e., triple therapy) for 30 days and afterwards stopped aspirin and maintained treatment with Vora plus clopidogrel (i.e., dual therapy) for other 30 days. PD testing using 5 different assays was conducted at 3 time-points: baseline (while on DAPT); after 30 days of triple therapy; after 30 days of dual therapy. The primary endpoint was the non-inferiority of CAT (Collagen-ADP-TRAP)-induced aggregation, a marker of global platelet reactivity, of Vora plus clopidogrel (dual therapy) vs Vora plus DAPT (triple therapy).
Results
The PD population was composed of a total of 64 patients (DM, n=30; non-DM, n=34). Although adding Vora to DAPT significantly reduced CAT-induced aggregation, stopping aspirin was associated with an increase in CAT-induced aggregation in both DM (mean difference=12; 95% CI: 3 to 21; p=0.010) and non-DM (mean difference=10; 95% CI: 4 to 16; p=0.003), thus not meeting the primary endpoint of non-inferiority (Figure). The magnitude of such increase was higher in DM compared with non-DM (p=0.036). Although Vora abolished TRAP-induced aggregation in both DM and non-DM patients, it did not affect markers of clot kinetics including speed of thrombin generation. Aspirin withdrawal was associated with a marked increase in makers sensitive to cyclooxygenase-1 (COX-1) blockade; markers of P2Y12 signaling were higher in DM compared to not DM after aspirin withdrawal.
CAT-induced aggregation
Conclusion
Adjunctive treatment with Vora reduces platelet-mediated thrombogenicity without affecting clot kinetics in both DM and non-DM patients while on DAPT. However, platelet-mediated thrombogenicity is increased after aspirin withdrawal, a phenomenon which is enhanced in DM patients underscoring the pivotal contribution of the COX-1 signaling pathway in these high risk patients.
Acknowledgement/Funding
The study was supported in part by an investigator initiated study grant from Merck
Collapse
Affiliation(s)
- F Franchi
- University of Florida College of Medicine, Jacksonville, United States of America
| | - F Rollini
- University of Florida College of Medicine, Jacksonville, United States of America
| | - V Kairouz
- University of Florida College of Medicine, Jacksonville, United States of America
| | - J Rivas
- University of Florida College of Medicine, Jacksonville, United States of America
| | - A Rivas
- University of Florida College of Medicine, Jacksonville, United States of America
| | - M Agarwal
- University of Florida College of Medicine, Jacksonville, United States of America
| | - M Briceno
- University of Florida College of Medicine, Jacksonville, United States of America
| | - M Wali
- University of Florida College of Medicine, Jacksonville, United States of America
| | - A Nawaz
- University of Florida College of Medicine, Jacksonville, United States of America
| | - G Silva
- University of Florida College of Medicine, Jacksonville, United States of America
| | - Z Shaikh
- University of Florida College of Medicine, Jacksonville, United States of America
| | - D Soffer
- University of Florida College of Medicine, Jacksonville, United States of America
| | - M M Zenni
- University of Florida College of Medicine, Jacksonville, United States of America
| | - T A Bass
- University of Florida College of Medicine, Jacksonville, United States of America
| | - D J Angiolillo
- University of Florida College of Medicine, Jacksonville, United States of America
| |
Collapse
|
3
|
Franchi F, Rollini F, Rivas J, Rivas A, Agarwal M, Briecno M, Wali M, Nawaz A, Silva G, Shaikh Z, Pineda A, Soffer D, Zenni MM, Bass TA, Angiolillo DJ. P1934Platelet inhibitory profiles of prasugrel versus ticagrelor in patients with CYP2C19 loss-of-function genotypes undergoing percutaneous coronary intervention: results of a randomized feasibility study. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz748.0681] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Background
Although clopidogrel is the most widely used P2Y12 inhibitor, loss-of-function (LOF) allelic variants located within the hepatic cytochrome P450 (CYP) 2C19 gene lead to attenuated bioactivation, increased rates of high platelet reactivity (HPR), and worse outcomes in patients undergoing percutaneous coronary intervention (PCI). Drug regulating authorities have suggested using alternative P2Y12 inhibitors (i.e., prasugrel or ticagrelor) in these patients. However, tailoring antiplatelet therapy in clinical practice according to results of genetic testing has been limited due to lack of access to promptly available results. Moreover, there are no head-to-head pharmacodynamic (PD) comparisons of prasugrel vs ticagrelor among patients with CYP2C19 LOF alleles.
Purpose
The aim of this study was to evaluate the feasibility of using rapid genetic testing in clinical practice and to compare the PD effects of prasugrel vs ticagrelor in patients undergoing PCI with CYP2C19 LOF alleles.
Methods
This was a prospective, randomized study conducted in patients with stable coronary artery disease and non-ST elevation acute coronary syndrome scheduled for left heart catheterization (LHC) with the intent to undergo PCI. Patients underwent rapid genetic testing using the Spartan RX assay, which defines CYP2C19 genetic status within 1 hour, allowing patients to be genotyped the same day of their LHC. Patients who were carriers of at least one LOF (*2 or *3) allele were randomized to receive either prasugrel [60mg loading dose (LD) - 10mg/day maintenance dose (MD)] or ticagrelor (180mg LD - 90mg b.i.d MD). Blood samples for PD analysis by VerifyNow were collected at 5 time points: baseline (prior to PCI), 30 minutes, 2 hours, 24 hours (or at hospital discharge whichever came first), and 1–4 weeks post-LD. All patients were treated with aspirin. The primary endpoint of our study was the non-inferiority in platelet reactivity, measured as PRU, at 24 hours of prasugrel vs ticagrelor in LOF allele carriers.
Results
A total of 781 consecutive patients scheduled for LHC were genotyped, of whom 223 (28.5%) were carriers of at least one LOF. Of these, 65 patients underwent PCI and randomized to prasugrel (n=32) vs ticagrelor (n=33). PRU levels at 24 hours were 33 vs 36 (prasugrel vs ticagrelor; mean difference = −3; 95% CI: −28 to 22; p=0.814) meeting the primary endpoint of non-inferiority. Both prasugrel and ticagrelor significantly reduced PRU to a similar extent with no differences between groups at all other time points (Figure). Accordingly, HPR rates were low and similar between groups.
PRU by VerifyNow
Conclusion
Rapid genetic testing using the Spartan assay is feasible providing results in a timely fashion in a real-world clinical practice of patients undergoing PCI. Among patients with CYP2C19 LOF carrier status, prasugrel and ticagrelor are associated with similar levels of platelet inhibition.
Acknowledgement/Funding
Genetic testing was provided by Spartan RX
Collapse
Affiliation(s)
- F Franchi
- University of Florida College of Medicine, Jacksonville, United States of America
| | - F Rollini
- University of Florida College of Medicine, Jacksonville, United States of America
| | - J Rivas
- University of Florida College of Medicine, Jacksonville, United States of America
| | - A Rivas
- University of Florida College of Medicine, Jacksonville, United States of America
| | - M Agarwal
- University of Florida College of Medicine, Jacksonville, United States of America
| | - M Briecno
- University of Florida College of Medicine, Jacksonville, United States of America
| | - M Wali
- University of Florida College of Medicine, Jacksonville, United States of America
| | - A Nawaz
- University of Florida College of Medicine, Jacksonville, United States of America
| | - G Silva
- University of Florida College of Medicine, Jacksonville, United States of America
| | - Z Shaikh
- University of Florida College of Medicine, Jacksonville, United States of America
| | - A Pineda
- University of Florida College of Medicine, Jacksonville, United States of America
| | - D Soffer
- University of Florida College of Medicine, Jacksonville, United States of America
| | - M M Zenni
- University of Florida College of Medicine, Jacksonville, United States of America
| | - T A Bass
- University of Florida College of Medicine, Jacksonville, United States of America
| | - D J Angiolillo
- University of Florida College of Medicine, Jacksonville, United States of America
| |
Collapse
|
4
|
Hong B, Adcock S, Shaikh Z. Evaluation of the 2WW head and neck cancer referral system: a prospective study. Int J Oral Maxillofac Surg 2015. [DOI: 10.1016/j.ijom.2015.08.127] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
5
|
Patil G, Khedkar U, Shaikh Z. Association of mortality with years of education in patients with ST-segment elevation myocardial infarction treated with fibrinolysis. Indian Heart J 2014. [DOI: 10.1016/j.ihj.2014.10.199] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
|
6
|
Shaikh Z, Perry M, Morrissey D, Ahmad M, Del Buono A, Maffulli N. Achilles Tendinopathy in Club Runners. Int J Sports Med 2012. [DOI: 10.1055/s-0032-1313785] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Affiliation(s)
- Z. Shaikh
- Barts and The London School of Medicine and Dentistry, Centre for Sports and Exercise Medicine, United Kingdom
| | - M. Perry
- Barts and The London School of Medicine and Dentistry, Centre for Sports and Exercise Medicine, United Kingdom
| | - D. Morrissey
- Barts and The London School of Medicine and Dentistry, Centre for Sports and Exercise Medicine, United Kingdom
| | - M. Ahmad
- Barts and The London School of Medicine and Dentistry, Radiology, Queen Mary University of London, United Kingdom
| | - A. Del Buono
- Department of Orthopaedic and Trauma Surgery, University Campus Bio Medico, Rome, Italy
| | - N. Maffulli
- Barts and The London School of Medicine and Dentistry, Centre for Sports and Exercise Medicine, United Kingdom
| |
Collapse
|
7
|
Abstract
Ultrasound (US) changes within the Achilles tendon are present in asymptomatic Achilles individuals. We assessed the association of US signs with symptoms of Achilles tendinopathy in a study group of club level running athletes and in a control group of athletes training at least 2 times per week. The Achilles tendon was assessed in its entirety on longitudinal US scans, at the musculotendinous junction (MTJ), the calcaneal insertion site, and at a midtendon point. 25 middle distance runners, 19 males and 6 females, aged from 18 to 58, were enrolled in each group. When compared to control athletes, club level runners presented significantly increased tendon thickness (p=0.046) at the musculo-tendinous junction, and increased tendon thickness, with no statistical significance, at the other landmarks points. Although club level runners were significantly more symptomatic and predisposed to develop signs of tendinopathy than control athletes (p=<0.001), ultrasound abnormalities were not significantly associated with local symptoms complained at the US investigation time. Prospective studies on asymptomatic athletes are needed to define the predictive value of US signs of Achilles tendinopathy in the development of symptoms in the long-term.
Collapse
Affiliation(s)
- Z Shaikh
- Barts and The London School of Medicine and Dentistry, Centre for Sports and Exercise Medicine, London, United Kingdom
| | | | | | | | | | | |
Collapse
|
8
|
Perry M, Morrissey D, Emerson C, Teatino R, Shaikh Z, Mitchell S, O'Driscoll G, Ahmad M, Maffulli N. Achilles tendon thickness, ultrasound signs and symptoms in skaters, gymnasts, elite soccer players, club athletes and healthy sedentary adults - a cross-sectional study. Br J Sports Med 2011. [DOI: 10.1136/bjsm.2010.081554.16] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
9
|
Shaikh Z, de Villa M, Hopkinson N. Hypoxaemia in COPD: looking beyond the lungs. Breathe (Sheff) 2009. [DOI: 10.1183/18106838.0504.363] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
|
10
|
Abstract
Stroke research has progressed in leaps and bounds in the past decades. A driving force is the increasing availability of new research tools in this field (eg, animal stroke models). Animal stroke models have been extensively applied to advance our understanding of the mechanisms of ischemic brain injury and to develop novel therapeutic strategies for reducing brain damage after a stroke. Animal stroke models have been useful in characterizing the molecular cascades of injury processes. These "injury pathways" are also the targets of therapeutic interventions. The major achievements made in the past 2 decades applying animal stroke models include 1) the identification of the mediator role of excitotoxin and oxygen free radicals in ischemic brain injury; 2) the confirmation of apoptosis as a major mechanism of ischemic cell death; 3) the characterization of postischemic gene expression; 4) the delineation of postischemic inflammatory reaction; 5) the application of transgenic mice to confirm the roles of purported mediators in ischemic brain injury; 6) development of novel magnetic resonance imaging sequences for early noninvasive detection of ischemic brain lesions; and, 7) the development of novel therapeutic strategies based on preclinical findings derived from animal stroke models.
Collapse
Affiliation(s)
- S H Ahmed
- Department of Neurology, Box 8111, Washington University School of Medicine, 660 S. Euclid Ave. St. Louis, MO 63110, USA.
| | | | | | | |
Collapse
|
11
|
Wasay M, Bakshi R, Dubey N, Mohr S, Shaikh Z, Kinkel WR. Diagnostic yield of head computed tomography scanning in the evaluation of 112 consecutive patients with dizziness. Ann Emerg Med 1999. [DOI: 10.1016/s0196-0644(99)80107-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
12
|
Abstract
It has been theorized that adenosine is a leading candidate for the metabolite responsible for ischemic muscle pain. The purpose of this study was to determine the effect of the non-selective adenosine receptor antagonist, caffeine, on ischemic skeletal muscle contraction pain. Seven healthy adult volunteers with no history of pain disorders, systemic disease, or habitual caffeine use, were chosen for the two-session, cross-over, double-blind study. Every subject received either 200 mg of caffeine (NoDoz, Bristol-Myers) or identical placebo 1 hour before each of the two trials. Ischemia of the forearm was achieved by inflation of a blood pressure cuff to 250 mm Hg. Forearm muscle activity was generated by performance of wrist curis using a 5-gram bar at a rate of 40 cycles per minute. Pain was rated at 15-second intervals for 1 minute using a visual analog scale (0 to 10) with verbal descriptors. Significance was determined by univariate and multivariate analyses of variance and covariance including repeated measures. Pain ratings at 15 seconds in the caffeine trial were significantly lower (P < 0.02) than those in the placebo trial. This effect continued at 30 seconds (P < 0.05). However, by 45 seconds, pain in the caffeine trial was not significantly lower (P = 0.4) than that in the placebo trial. These results show that high-dose caffeine exhibits considerable analgesic efficacy in experimental muscle pain, adding support for a role of adenosine in producing ischemic muscle contraction pain.
Collapse
Affiliation(s)
- D E Myers
- Department of Oral Medicine, University of Pittsburgh (Penn) School of Dental Medicine 15261, USA
| | | | | |
Collapse
|
13
|
Shaikh Z, Khan MH, Qamar R. Clinical profile of 100 cases of liver abscess. J PAK MED ASSOC 1989; 39:256-9. [PMID: 2513420] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
One hundred patients with liver abscess were studied for clinical features and complications. They were diagnosed by radiography, ultrasonography, serology and by needle aspiration. A variety of interesting clinical, haematological and ultrasonographic findings were observed. Literature on liver abscess was reviewed and results compared.
Collapse
|
14
|
Khan MH, Qamar R, Shaikh Z. Serodiagnosis of amoebic liver abscess by IHA method. J PAK MED ASSOC 1989; 39:262-4. [PMID: 2513422] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
Serological test based on IHA (Indirect Haemagglutination Method) was performed in 100 cases of hepatic abscess. The test was 100% sensitive and 94% specific. The cut off point of antibody titer between normal population and patients with invasive amoebiasis was 1:128. Antibody titer in amoebic liver abscess was 1:5242 +/- 2795. A significant (P less than 0.001) correlation was found between total leucocyte count and antibody titer.
Collapse
|